What were the findings in early human studies on pulmonary hypertension?
After VIP intervention, mean pulmonary artery pressure decreased, and indicators such as cardiac output improved.[1] ↗
8 patients with primary pulmonary hypertension; historical exploratory study.
2003 Very minimal, non-confirmatory study; special clinical preparation and research conditions, does not represent effects for other lung diseases or general commercial products.
View the Article Title and Full Citation+
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.
The Journal of Clinical Investigation · Volume, Issue, Year 2003
First published 2003-05-01 · PMID 12727925
DOI 10.1172/JCI17500







